Nuvation Bio Receivables 2020-2024 | NUVB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Nuvation Bio receivables from 2020 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Nuvation Bio receivables from 2020 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.5B
Vertex Pharmaceuticals (VRTX)	$121.6B
Gilead Sciences (GILD)	$111.4B
Bristol Myers Squibb (BMY)	$110.2B
Regeneron Pharmaceuticals (REGN)	$93B
CSL (CSLLY)	$90B
GSK (GSK)	$76.4B
Argenex SE (ARGX)	$35.6B
Alnylam Pharmaceuticals (ALNY)	$35.3B
BioNTech SE (BNTX)	$26.5B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$23.9B
Moderna (MRNA)	$21B
BeiGene (BGNE)	$19.9B
Genmab (GMAB)	$14.9B
Incyte (INCY)	$14.7B
Exact Sciences (EXAS)	$12.9B
BioMarin Pharmaceutical (BMRN)	$12.7B
Vaxcyte (PCVX)	$12B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.8B
Insmed (INSM)	$11.7B
QIAGEN (QGEN)	$9.8B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.3B
Revolution Medicines (RVMD)	$9.2B
Intra-Cellular Therapies (ITCI)	$9.2B
Roivant Sciences (ROIV)	$8.6B
Viking Therapeutics (VKTX)	$8.1B
Legend Biotech (LEGN)	$8.1B